|
 Gene description for CLDN12 |
| Gene name |
claudin 12 |
| Gene symbol |
CLDN12 |
| Other names/aliases |
- |
| Species |
Homo sapiens |
| Database cross references - CLDN12 |
| ExoCarta |
ExoCarta_9069 |
| Vesiclepedia |
VP_9069 |
| Entrez Gene |
9069 |
| HGNC |
2034 |
| MIM |
611232 |
| UniProt |
P56749
|
| CLDN12 identified in exosomes derived from the following tissue/cell type |
|
Prostate cancer cells
|
25844599
|
|
Prostate cancer cells
|
25844599
|
| Gene ontology annotations for CLDN12 |
|
|
| Experiment description of studies that identified CLDN12 in exosomes |
| 1 |
| Experiment ID |
275 |
| MISEV standards |
|
✔
EM
|
Biophysical techniques |
|
✔
TSG101|Alix|RAB5A|CD9|CD82|CD63|CD81
|
Enriched markers |
|
✔
AIF
|
Negative markers |
|
✔
NTA
|
Particle analysis
|
|
| Identified molecule |
protein
|
| Identification method |
Mass spectrometry
|
| PubMed ID |
25844599
|
| Organism |
Homo sapiens |
| Experiment description |
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. |
| Authors |
Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullen A, Yachnin J, Nilsson S, Panaretakis T. |
| Journal name |
Oncotarget
|
| Publication year |
2015 |
| Sample |
Prostate cancer cells |
| Sample name |
DU145 - Docetaxel sensitive |
| Isolation/purification methods |
Filtration
Ultracentrifugation
Sucrose density gradient |
| Flotation density |
1.12-1.19 g/mL
|
| Molecules identified in the study |
Protein |
| Methods used in the study |
Mass spectrometry/Flow cytometry/Western blotting |
|
|
| 2 |
| Experiment ID |
274 |
| MISEV standards |
|
✔
EM
|
Biophysical techniques |
|
✔
TSG101|Alix|RAB5A|CD9|CD82|CD63|CD81
|
Enriched markers |
|
✔
AIF
|
Negative markers |
|
✔
NTA
|
Particle analysis
|
|
| Identified molecule |
protein
|
| Identification method |
Mass spectrometry
|
| PubMed ID |
25844599
|
| Organism |
Homo sapiens |
| Experiment description |
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. |
| Authors |
Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullen A, Yachnin J, Nilsson S, Panaretakis T. |
| Journal name |
Oncotarget
|
| Publication year |
2015 |
| Sample |
Prostate cancer cells |
| Sample name |
DU145 - Docetaxel resistant |
| Isolation/purification methods |
Filtration
Ultracentrifugation
Sucrose density gradient |
| Flotation density |
1.13-1.18 g/mL
|
| Molecules identified in the study |
Protein |
| Methods used in the study |
Mass spectrometry
Flow cytometry
Western blotting |
|
|
| Protein-protein interactions for CLDN12 |
|
|
| Pathways in which CLDN12 is involved |
|
|
|
